Orthocell Limited (ASX:OCC)

Market Cap	217.80M -25.2%
Revenue (ttm)	9.33M +23.7%
Net Income	-12.48M
EPS	-0.05
Shares Out	272.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,270
Open	0.8200
Previous Close	0.8350
Day's Range	0.7900 - 0.8200
52-Week Range	0.7000 - 1.6000
Beta	-0.07
Analysts	Strong Buy
Price Target	1.23 (+53.75%)
Earnings Date	Jul 13, 2026

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OCC

Financial Performance

In fiscal year 2025, Orthocell's revenue was 7.55 million, an increase of 42.05% compared to the previous year's 5.32 million. Losses were -8.57 million, 19.3% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for OCC stock is "Strong Buy." The 12-month stock price target is $1.23, which is an increase of 53.75% from the latest price.

Price Target

$1.23

(53.75% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error